エルロチニブ獲得耐性肺癌細胞株における微小管阻害剤の交差耐性 by 水内, 寛 & Mizuuchi, Hiroshi
RESEARCH ARTICLE
Collateral Chemoresistance to Anti-
Microtubule Agents in a Lung Cancer Cell Line
with Acquired Resistance to Erlotinib
Hiroshi Mizuuchi1,2, Kenichi Suda1,2, Katsuaki Sato1, Shuta Tomida3, Yoshihiko Fujita3,
Yoshihisa Kobayashi1, Yoshihiko Maehara2, Yoshitaka Sekido4, Kazuto Nishio3,
Tetsuya Mitsudomi1*
1 Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
Japan, 2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University,
Fukuoka, Japan, 3 Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama,
Japan, 4 Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
* mitsudom@surg.med.kindai.ac.jp
Abstract
Various alterations underlying acquired resistance to epidermal growth factor receptor-tyro-
sine kinase inhibitors (EGFR-TKIs) have been described. Although treatment strategies
specific for these mechanisms are under development, cytotoxic agents are currently em-
ployed to treat many patients following failure of EGFR-TKIs. However, the effect of TKI re-
sistance on sensitivity to these cytotoxic agents is mostly unclear. This study investigated
the sensitivity of erlotinib-resistant tumor cells to five cytotoxic agents using an in vitro
EGFR-TKI-resistant model. Four erlotinib-sensitive lung adenocarcinoma cell lines and
their resistant derivatives were tested. Of the resistant cell lines, all but one showed a similar
sensitivity to the tested drugs as their parental cells. HCC4006ER cells with epithelial mes-
enchymal transition features acquired resistance to the three microtubule-targeting agents,
docetaxel, paclitaxel and vinorelbine, but not to cisplatin and gemcitabine. Gene expression
array and immunoblotting demonstrated that ATP-binding cassette subfamily B, member 1
(ABCB1) was up-regulated in HCC4006ER cells. ABCB1 knockdown by siRNA partially re-
stored sensitivity to the anti-microtubule agents but not to erlotinib. Moreover, the histone
deacetylase inhibitor entinostat sensitized HCC4006ER cells to anti-microtubule agents
through ABCB1 suppression. Our study indicates that sensitivity of tumor cells to cytotoxic
agents in general does not change before and after failure of EGFR-TKIs. However, we de-
scribe that two different molecular alterations confer acquired resistance to EGFR-TKIs and
cytotoxic agents, respectively. This phenomenon should be kept in mind in selection of sub-
sequent therapy after failure of EGFR-TKIs.
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Introduction
Adenocarcinoma is the most common histological subtype of lung cancer, and somatic muta-
tion of the epidermal growth factor receptor (EGFR) is present in approximately 40% and 20%
of these tumors in East-Asians and Caucasians, respectively [1]. Treatment of lung adenocarci-
noma patients with EGFR tyrosine kinase inhibitors (TKIs) prolongs progression-free survival
compared with conventional cytotoxic chemotherapy [2–5]. However, the development of ac-
quired resistance to EGFR-TKIs is almost inevitable. Many molecular or histological aberra-
tions underlying this acquired resistance have been reported, including EGFR T790M
secondary mutation,MET amplification, ERBB2 amplification, hepatocyte growth factor over-
expression, epithelial to mesenchymal transition (EMT), and small cell lung cancer transfor-
mation [6,7].
Strategies to cope with acquired resistance to EGFR-TKIs that are based on each different
resistant mechanism would be ideal, and such approaches are currently being developed. How-
ever, in current clinical practice, these patients are typically treated with cytotoxic chemothera-
peutic agents, selection of which is often empirical. It is also unclear whether acquired
resistance to EGFR-TKIs affects sensitivity to cytotoxic drugs.
In this study, we evaluate the growth inhibitory effects of these cytotoxic drugs by compar-
ing cells resistant to an EGFR-TKI with their parent cells using an in vitromodel. Isogenic re-
sistant clones derived from parental cells have a common genetic background, and this
resistance model is able to be used to evaluate the influence of different resistant mechanisms
on chemosensitivity.
Materials and Methods
Cell lines and reagents
The human lung adenocarcinoma cell lines HCC827, HCC4006 and H358 were kind gifts from
Dr AF Gazdar (Hamon Center for Therapeutic Oncology Research, University of Texas South-
western Medical Center at Dallas). These cell lines have been commonly used in in vitro experi-
ments [8–13]. PC9 cells were kindly provided from Dr K Nishio (Department of Genome
Biology, Kinki University Faculty of Medicine). This cell line has also been commonly used in
previous researches elsewhere [14,15]. Acquired resistant cell lines established from these cells,
PC9/ZD cells and HCC827TRB10 cells, were kindly provided from Dr K Nishio and Dr K Fur-
ugaki (Chugai Pharmaceutical Co., Ltd.), respectively [15,16]. HCC827ER, HCC827EPR,
HCC4006ER and H358ER were established in our previous work [9,10,17]. Table 1 provides a
summary of the mutational status and sensitivity to erlotinib of these cell lines [9,10,15–17].
Cells were cultured in RPMI1640 medium supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS) at 37°C in a humidified incubator with 5% CO2. Cisplatin (CDDP), gemcita-
bine (GEM), docetaxel (DOC), paclitaxel (PAC), vinorelbine (VNR), erlotinib, and entinostat
were purchased from Selleck Chemicals (Houston, TX).
Growth inhibition assay
Cell viability was measured using a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto,
Japan) as previously described [17]. Briefly, 3 × 103 cells (2 × 103 cells for HCC827TRB10)
were plated into each well of 96-well flat-bottomed plates and grown in RPMI-1640 containing
10% FBS. After 24 hours, dimethyl sulfoxide (DMSO), CDDP, GEM, DOC, PAC, VNR, and
erlotinib with or without entinostat were added at the indicated drug concentration, and cells
were incubated for an additional 72 hours. A colorimetric assay was performed after addition
of 10 μl Cell Counting Kit-8 reagent to each well, and the plates were incubated at 37°C for 2–4
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hours. Absorbance at 450nm was read using a multiplate reader (Tecan, Männedorf, Switzer-
land). Percent growth was expressed relative to DMSO-treated controls.
RNA isolation and gene expression array analysis
Gene expression array analyses were carried out to assess differences between HCC4006 and
HCC4006ER cells as previously described [18]. Briefly, cells were cultured without erlotinib
until subconfluency. After an 8 hour-exposure to 2 μM erlotinib, total RNA was isolated using
mirVana miRNA Isolation Kit (Qiagen, Venlo, the Netherlands). RNA (100 ng) from each
sample was processed for hybridization using GeneChip Human Genome U133 Plus 2.0 Array
(Affymetrix, Santa Clara, CA). After hybridization, the chips were processed using a High-Res-
olution Microarray Scanner Genechip Scanner 3000 7G (Affymetrix). The Robust Multichip
Averaging (RMA) procedure was performed for normalization using the open-source R
programming environment.
Antibodies and western blot analysis
Anti-E-cadherin, anti-ATP-binding cassette subfamily B, member 1 (ABCB1), anti-class III
beta-tubulin (TUBB3) and anti-beta-actin antibodies were purchased from Cell Signaling
Technology (Beverly, MA).
Preparation of total cell lysates and immunoblotting was performed as previously described
[17]. Cells were cultured without erlotinib until subconfluency, and media was changed to
RPMI with 10% FBS containing DMSO or 1 μM entinostat. After 72 hours, cells were rinsed
with phosphate-buffered saline (PBS), lysed in sodium dodecyl sulfate (SDS) buffer and ho-
mogenized. Approximately 30 μg of total cell lysate protein was subjected to SDS polyacryl-
amide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Bio-Rad,
Hercules, CA). After blocking with 2.5% nonfat dry milk and 2.5% bovine serum albumin in
PBS, membranes were incubated with primary antibodies (1:1000) overnight, washed with
PBS, reacted with secondary antibody (1:1000), treated with ECL solution (GE Healthcare,
Fairfield, CT). Chemiluminescence was detected by EOS Kiss X6i (Canon, Tokyo, Japan). Ex-
pression values of TUBB3 relative to beta-actin were determined using Just TLC software (Swe-
day, Lund, Sweden).
Table 1. The characteristics of EGFR-TKI sensitive cell lines and their resistant clones.
Cell lines Driver Resistant mechanisms Erlotinib IC50(μM)
HCC827 EGFR del19 - 0.0065
HCC827ER(8) MET amplification 6.9
HCC827EPR(8) T790M 7.1
HCC827TRB10(12) loss of amplified EGFR 5.7
HCC4006 EGFR del19 - 0.030
HCC4006ER(9) EMT >10
PC9 EGFR del19 - 0.023
PC9/ZD(11) T790M 2.2
H358 KRAS G12C - 0.12
H358ER(10) IGF1R hyperactivation 3.3
Abbreviations: EMT, epithelial mesenchymal transition.
doi:10.1371/journal.pone.0123901.t001
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Preparation of cell block and immunohistochemistry
Cells grown to subconfluency were trypsinized, centrifuged and fixed with 15% neutral buff-
ered formalin for 3 hours. Following centrifugal separation and removal of solution, the algi-
nate sodium containing pellet was turned into a gel by drop of calcium chloride. These gels
were embedded in paraffin.
Sections (4 μm) were deparaffinized and heat-induced epitope retrieval was performed with
Target Retrieval Solution, pH 9 (Dako, Carpinteria, CA). Slides were treated with 3% hydrogen
peroxide for 30 min and then incubated with a primary anti-ABCB1 (P-glycoprotein) antibody
(1:100, Dako) overnight. Immunoreactions were detected using the Envision+ System-HRP
(Dako) according to manufacturer’s protocol. The reactions were visualized followed by count-
er staining with hematoxylin.
Reverse-transfection of small-interfering RNAs
Cells were reverse-transfected with 10 nM small interfering RNAs (siRNAs) mixed with Lipo-
fectamine RNAiMAX (Invitrogen, Carlsbad, CA). The validated siRNAs specific for ABCB1
(ABCB1-1, 50-CGAUACAUGGUUUUCCGAU-30; ABCB1-2, 50-GUUUGUCUACAGUUC
GUAA-30), CDH1 (50-CGUAUACCCUGGUGGUUCA-30) and nonspecific siRNAs were pur-
chased from Applied Biosystems (Foster City, CA). Twenty-four hours after reverse-transfec-
tion, the indicated drugs were added, and cell viability was measured using the Cell Counting
Kit 8 after an additional 72 hours.
Results
All cell lines with acquired resistance to erlotinib except HCC4006ER
demonstrated similar sensitivity to cytotoxic drugs compared with their
parental cells
We first studied the sensitivity of cell lines to five cytotoxic agents that are commonly used in
the treatment of NSCLC. CDDP, GEM, DOC, PAC and VNR sensitivity was assessed in
HCC827, HCC4006, PC9 and H358 cells, as well as their EGFR-TKI resistant derivatives. In
HCC827 cells and their three EGFR-TKI resistant clones (HCC827ER, HCC827EPR and
HCC827TRB10), we failed to detect a difference in sensitivity to any of the five cytotoxic agents
(Fig 1 and Table 2). This was also case with PC9, H358 and their resistant clones. On the other
hand, in HCC4006ER cells, IC50 values for DOC, PAC and VNR were increased by approxi-
mately 41-, 43-, 28-fold, respectively (Fig 1 and Table 2). All three drugs to which cells showed
decreased sensitivity (DOC, PAC and VNR) were anti-microtubule drugs, acting either
through inhibition of microtubule polymerization (vinca alkaloids) or by depolymerization
(taxanes).
ABCB1 overexpression induces insensitivity to anti-microtubule drugs in
HCC4006ER cells
HCC4006ER cells were established by stepwise exposure to erlotinib (from 20 nM to 2 μM)
over 4 months in our previous work [10]. To explore the molecular alterations underlying ac-
quired resistance to anti-microtubule agents, we performed a gene expression array analysis
comparing HCC4006ER cells with parental HCC4006 cells. Expression of CDH1 in
HCC4006ER cells was significantly decreased compared with HCC4006 cells, confirming the
previous report (Table 3) [10]. Additionally, we observed increased expression of ZEB1 and
ZEB2 which both regulate EMT by 27- and 23-fold, respectively. On the other hand, stem cell
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markers such as OCT4, SOX2, NANOG and GATA4 and cancer stem cell (CSC)–like markers
including ALDH1A1, CD44 and CD133 were not upregulated (Table 4).
Amongst the top 50 up-regulated and 50 down-regulated genes in HCC4006ER cells com-
pared with HCC4006 parental cells (Table 2), we identified that ATP-binding cassette subfami-
ly B, member 1 (ABCB1) was up-regulated by approximately 40-fold in HCC4006ER cells. On
the other hand, no other ABC transporter family member was overexpressed to a similar extent
in HCC4006ER cells (Table 5). Overexpression of ABCB1, a drug efflux pump has been re-
ported to confer inherent or acquired resistance to anti-microtubule drugs [19–24].
Fig 1. Anti-proliferative effects of paclitaxel in EGFR-TKI sensitive and their resistant clones. Tumor
cells (2–3×103 cells per well) were incubated with various concentrations of paclitaxel for 72 hours. Percent
growth relative to DMSO-treated controls was determined by Cell Counting Kit-8 assay.
doi:10.1371/journal.pone.0123901.g001
Table 2. IC50 values for cytotoxic agents in EGFR-TKI sensitive and their resistant clones.
Cell lines CDDP (μM) GEM (nM) DOC (nM) PTX (nM) VNR (nM)
HCC827 136 50 0.90 4.5 3.3
HCC827ER 65 15 2.0 7.1 3.5
HCC827EPR 57 63 0.91 3.4 2.3
HCC827TRB10 120 28 3.1 24.0 6.1
HCC4006 84 >10,000 <0.46 1.1 1.2
HCC4006ER 49 >10,000 19 47 33
PC9 140 15 0.64 3.2 8.7
PC9/ZD 170 26 0.48 3.3 8.6
H358 500 <4.6 0.64 1.8 1.5
H358ER 530 6.5 0.97 2.9 1.5
Abbreviations: CDDP, cisplatin; GEM, gemcitabine; DOC, docetaxel; PTX, paclitaxel; VNR, vinorelbine.
doi:10.1371/journal.pone.0123901.t002
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Immunoblotting and immunohistochemistry of cell blocks also confirmed the overexpression
of ABCB1 protein in HCC4006ER cells but not in parental HCC4006 cells (Fig 2).
Moreover, increased expression of classⅢ beta-tubulin (TUBB3) has also been reported to
be a predictive marker for clinical outcome of taxane/vinorelbine-based chemotherapy [25].
However, immunoblotting demonstrated that the expression level of TUBB3 in HCC4006ER
cells was not altered (Fig 2). Gene expression array also revealed that alteration of TUBB3 was
Table 3. Top 30 genes altering expression between HCC4006 and HCC4006ER cells.
Upregulated genes in HCC4006ER cells compared with HCC4006
cells
Downregulated genes in HCC4006ER cells compared with HCC4006
cells
Gene Symbol log2 (ratio) Gene Symbol log2 (ratio) Gene Symbol log2 (ratio) Gene Symbol log2 (ratio)
ODZ2 8.67 ADAMTS1 5.27 CEACAM6 -10.71 COL4A3 -6.60
COL8A1 7.92 PADI2 5.06 CDH1 -9.03 HS6ST2 -6.51
SFRP2 6.80 ABCB1/ABCB4 5.05 TMC5 -8.77 FXYD3 -6.48
RGS4 6.69 ALPK2 4.99 CEACAM6 -8.38 LCN2 -6.37
NNMT 6.55 NEFM 4.98 TMC5 -8.38 HS6ST2 -6.33
244567_at 6.48 LAMA4 4.98 AGR2 -8.34 C15orf48 -6.31
GAS1 6.41 STON1 4.96 TMC5 -7.89 RAB25 -6.21
GNG4 6.28 238512_at 4.96 TMEM30B -7.49 PTGS2 -6.20
PDE1A 6.20 C14orf132 4.93 ESRP1 -7.42 C4orf19 -6.19
BEX1 6.11 SLC16A1 4.90 MUC20 -7.29 CDH3 -6.19
CNN1 6.02 CNRIP1 4.89 PCDH20 -7.18 ITGB6 -6.18
GNG4 5.92 PAPPA 4.86 SPOCK2 -7.12 HOPX -6.10
PTX3 5.86 NRK 4.83 TSPAN8 -7.12 NTM -6.06
FAM101B 5.86 THBS2 4.81 C1orf116 -7.11 RNASE1 -6.05
GNG4 5.86 PDE1A 4.79 KRT19 -7.07 DLL1 -6.04
1561064_a_at 5.67 ZEB1 4.78 FGF13 -6.89 PIGR -5.95
COL11A1 5.63 LOC100288985 4.76 TMC5 -6.86 EHF -5.93
HMCN1 5.63 ADAMTS5 4.76 MAL2 -6.79 MUC20 -5.86
SHISA2 5.60 SLC16A1 4.69 NPNT -6.78 STEAP4 -5.84
ADAMTS2 5.58 CLDN11 4.69 GPR87 -6.71 SCNN1A -5.78
SLC16A1 5.42 RNF182 4.63 MPZL2 -6.71 CEACAM5 -5.73
PAX6 5.42 ADAMTS5 4.61 SCEL -6.68 COL4A4 -5.73
AK5 5.38 COL12A1 4.61 GALNT3 -6.65 EHF -5.71
ABCB1 5.32 DCDC2 4.60 C4orf19 -6.63 NEBL -5.71
NNMT 5.32 NXF3 4.60 SPINK1 -6.60 LRRN1 -5.64
doi:10.1371/journal.pone.0123901.t003
Table 4. Relative expression levels of stem cell /cancer stem cell (CSC)-like markers in HCC4006ER
cells compared with HCC4006.
Type Gene Symbol log2 (ratio)
stem cell POU5F1 (OCT4) 0.17
SOX2 0.14
NANOG 0.08
GATA4 0.50
CSC-like ALDH1A1 -0.88
CD44 -1.11
PROM1(CD133) -2.37
doi:10.1371/journal.pone.0123901.t004
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less than 2 fold (data not shown). Since it is reported that docetaxel-resistant cell line expressed
~50-fold more TUBB3 than parental cells [26], we assumed that the contribution of TUBB3 in
our system was minimal.
We next evaluated the role of overexpressed ABCB1 in acquired resistance to anti-microtu-
bule drugs by using two validated siRNAs for ABCB1. siRNA-mediated knockdown of ABCB1
partially sensitized HCC4006ER cells to anti-microtubule agents (Fig 3). In contrast, ABCB1
depletion did not restore erlotinib sensitivity in HCC4006ER cells (Fig 3).
We also investigated whether loss of E-cadherin activity influences sensitivity to anti-micro-
tubule agents. Knockdown of CDH1 (gene encoding E-cadherin) in HCC4006 cells did not af-
fect sensitivity to any of the three anti-microtubule agents (Fig 4).
Entinostat alleviates resistance to anti-microtubule drugs via
suppression of ABCB1 in HCC4006ER cells
We next treated HCC4006ER cells with the class I histone deacetylase (HDAC) inhibitor enti-
nostat, which reverses EMT in HCC4006ER cells and restores sensitivity to erlotinib as de-
scribed in our previous study [10]. Here, entinostat did not alter sensitivity to anti-microtubule
agents in HCC4006 cells (Fig 5). However, this agent restored sensitivity to anti-microtubule
drugs in HCC4006ER cells (Fig 5). To explore the molecular mechanism which entinostat
achieves this, we examined the expression levels of ABCB1 in HCC4006ER cells with or with-
out exposure to 1 μM entinostat. Treatment with entinostat markedly reduced the expression
of ABCB1 protein after 72 hours (Fig 5).
Table 5. Relative expression levels of ABC transporter family in HCC4006ER cells compared with
HCC406.
Gene Symbol log2 (ratio) Gene Symbol log2 (ratio)
ABCA1 0.46 ABCC12 0.38
ABCA12 -4.17 ABCC13 0.23
ABCA13 -2.68 ABCC2 -0.38
ABCA2 0.37 ABCC3 -1.84
ABCA3 -0.45 ABCC4 2.02
ABCA4 -0.46 ABCC5 0.51
ABCA5 1.84 ABCC6 -0.80
ABCA6 0.05 ABCC8 0.56
ABCA7 -0.95 ABCC9 -0.21
ABCA8 -0.68 ABCD1 0.26
ABCA9 -0.33 ABCD2 0.04
ABCB1 5.32 ABCD3 0.90
ABCB10 -0.12 ABCD4 0.39
ABCB11 0.37 ABCE1 1.15
ABCB4 -0.26 ABCF1 0.64
ABCB5 0.54 ABCF2 0.65
ABCB6 0.26 ABCF3 -0.10
ABCB7 -0.51 ABCG1 -1.73
ABCB8 -0.03 ABCG2 -0.66
ABCB9 0.37 ABCG4 -0.16
ABCC1 -0.77 ABCG5 0.00
ABCC10 -0.86 ABCG8 0.35
ABCC11 0.47
doi:10.1371/journal.pone.0123901.t005
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Discussion
We have previously shown that HCC4006ER cells are resistant to erlotinib through acquisition
of EMT as characterized by the down-regulation of E-cadherin expression [10]. In the present
study, we observed that HCC4006 ER cells have a similar sensitivity to CDDP and GEM com-
pared with their parental cell line, but are more resistant to anti-microtubule agents. ABCB1
overexpression in HCC4006ER cells was responsible for this phenomenon. However, restora-
tion of sensitivity to anti-microtubule agents by ABCB1 siRNA was not complete. This may be
due to involvement of other genes than ABCB1 which was suggested by expression profiling or
incomplete suppression of ABCB1 gene expression in our system (Table 3). On the other hand,
Fig 2. Expression of proteins which were reported to be associated with sensitivity to anti-microtubule agents. (A) Protein expression was evaluated
by western blot analysis. Expression values of classⅢ beta-tubulin (TUBB3) relative to beta-actin were determined using Just TLC software. (B)
Representative images of HCC4006 and HCC4006ER cells immunohistochemically stained with antibodies to ATP-binding cassette subfamily B, member 1
(ABCB1).
doi:10.1371/journal.pone.0123901.g002
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ABCB1 expression was not related to sensitivity to erlotinib. In fact, Noguchi et al. previously
reported that ABCB1 induction in two lung cancer cell lines did not change sensitivity to erloti-
nib [27]. ABC transporters including ABCB1 have been reported to be implicated in promoting
cancer stem cell (CSC)-like properties [28]. Although our HCC4006ER cells did not show in-
creased expression of the other CSC-like markers (Table 5), Shien et al. have recently reported
similar observations that gefitinib-resistant HCC827 cells exhibiting both EMT features and
CSC properties with overexpression of ABCB1 were resistant to DOC and PAC [29]. There-
fore, this “collateral” cross-resistance to erlotinib and anti-microtubule agents resulted from
two distinct mechanisms, both of which were thought to be a cause of or result from EMT
(Fig 6).
Alternatively, there are several examples in which resistance to EGFR-TKI and chemothera-
peutic agents shared the same molecular mechanism. PTEN deficiency renders PC9 cells resis-
tant to cisplatin and also reduces their sensitivity to erlotinib [30]. AXL overexpression confers
resistance to gefitinib and cisplatin in HCC4006 and HCC827 cells [31]. These mechanisms
have also been reported to induce resistance to EGFR-TKIs [32,33]. Therefore, they can be
Fig 3. Effect of siRNA-mediated knockdown for ABCB1 in HCC4006ER cells. (A) Total cell lysates were
harvested 72 hours after reverse-transfection of negative control siRNA (siNC) or validated two siRNAs for
ATP-binding cassette subfamily B, member 1 (ABCB1) mixed with Lipofectamine RNAiMAX. (B-E) Tumor
cells were reverse-transfected at the same time plating into 96-wells and then incubated for 24 hours. They
were incubated with various concentrations of docetaxel, paclitaxel, vinorelbine and erlotinib for additional 72
hours. Percent growth relative to DMSO-treated controls was evaluated by Cell Counting Kit-8 assay.
doi:10.1371/journal.pone.0123901.g003
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regarded as “shared” cross-resistance to EGFR-TKI and cytotoxic drugs, in contrast to the “col-
lateral” resistance described here.
We also found that the class I HDAC inhibitor entinostat restored sensitivity to anti-micro-
tubule drugs through down-regulation of ABCB1 protein. We have previously shown that enti-
nostat restores sensitivity to erlotinib by promoting E-cadherin re-expression [10]. These
observations suggest that the EMT phenotype and ABCB1 overexpression observed in
HCC4006ER cells was at least partly attributable to histone deacetylation. Therefore, HDAC
inhibition might be an attractive approach to combine with EGFR-TKI to delay or suppress the
emergence of resistance.
In contrast to the above, five cell lines with acquired resistance to erlotinib, (two by T790M
secondary mutations, one each byMET amplification, loss of amplified EGFR and IGF1R
hyperactivation) did not exhibit any detectable change in sensitivity to five cytotoxic agents.
This is consistent with previous in vitro observations that demonstrated that EGFR-TKI resis-
tant cells with T790M orMET amplification showed sensitivity to cytotoxic agents similar to
that of their parental cells [14,29]. These alterations are considered to account for more than
60–70% of cases of acquired resistance to EGFR-TKIs [7]. Therefore, it can be hypothesized
that sensitivity to cytotoxic agents does not change before or after EGFR-TKI treatment and
Fig 4. Effect of siRNA-mediated knockdown for CDH1 in HCC4006ER cells. (A) Total cell lysates were harvested 72 hours after reverse-transfection of
negative control siRNA (siNC) or validated siRNAs for CDH1 which encodes E-cadherin mixed with Lipofectamine RNAiMAX. (B-D) Tumor cells were
reverse-transfected at the same time plating into 96-wells and then incubated for 24 hours. They were incubated with various concentrations of docetaxel,
paclitaxel and vinorelbine for additional 72 hours. Percent growth relative to DMSO-treated controls was evaluated by Cell Counting Kit-8 assay.
doi:10.1371/journal.pone.0123901.g004
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vice versa in the majority of cases. This hypothesis is consistent with the finding that overall
survival of the patients treated with platinum-doublet chemotherapy as the first line treatment
is not significantly different from that of patients treated with front-line EGFR-TKI, provided
that the cross-over was high enough in patients with lung cancer harboring EGFR mutation
[2,3].
In conclusion, we have demonstrated that erlotinib resitstance in a cell line harboring EGFR
mutation conferred a “collateral” resistance to anti-microtubule agents via upregulation of
ABCB1. However, this phenomenon appeared exceptional and chemosensitivity was not influ-
enced by EGFR-TKI resistance in most cases.
Fig 5. Additional effects of entinostat in HCC4006 and HCC4006ER cells. (A-C) Tumor cells were incubated with various concentrations of docetaxel (D),
paclitaxel (P) and vinorelbine (V) and with or without 1μM entinostat (E) for 72 hours. Percent growth relative to DMSO-treated controls was evaluated by Cell
Counting Kit-8 assay. (D) Total cell lysates were harvested after addition of 1μM entinostat.
doi:10.1371/journal.pone.0123901.g005
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